Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer
There is a need for improving the effect of first-line chemotherapy for lung cancer patients, preferably by using an approach with none or very few side effects.

In this trial the investigators incorporate δ-tocotrienol/placebo as a nutritional supplement on top of standard chemotherapy for patients with advanced non-small cell lung cancer.
Lung Cancer
DRUG: Day 1: Cisplatin 75 mg/m2|DRUG: Day 1: Vinorelbine 25 mg/m2|DRUG: Day 8: Capsule vinorelbine 50 mg/m2|DRUG: Day 1: Carboplatin AUC=5|DRUG: Day 1: Vinorelbine 30 mg/m2|DRUG: Day 8: Capsule vinorelbine 60 mg/m2|DIETARY_SUPPLEMENT: Tocotrienol 300 mg x 3 daily until progression|DRUG: Placebo 1 capsule x 3 daily until progression
Progression free survival, From date of randomization until date of first documented progression; assessed up to 36 months
There is a need for improving the effect of first-line chemotherapy for lung cancer patients, preferably by using an approach with none or very few side effects.

In this trial the investigators incorporate δ-tocotrienol/placebo as a nutritional supplement on top of standard chemotherapy for patients with advanced non-small cell lung cancer.